MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer.
Adaptor Proteins, Signal Transducing
/ genetics
Cell Line, Tumor
Cell Transformation, Viral
Female
Gene Expression Regulation, Neoplastic
Humans
Intracellular Signaling Peptides and Proteins
MicroRNAs
/ genetics
Oncogene Proteins, Viral
/ genetics
Papillomaviridae
/ genetics
Papillomavirus Infections
/ genetics
Protein Serine-Threonine Kinases
/ genetics
RNA, Neoplasm
/ genetics
Signal Transduction
Transcription Factors
/ genetics
Tumor Suppressor Proteins
/ genetics
Uterine Cervical Neoplasms
/ genetics
YAP-Signaling Proteins
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
20
01
2020
accepted:
13
05
2020
revised:
30
06
2020
pubmed:
20
6
2020
medline:
11
8
2020
entrez:
20
6
2020
Statut:
epublish
Résumé
Human papillomaviruses (HPV) are a major cause of malignancy worldwide. They are the aetiological agents of almost all cervical cancers as well as a sub-set of other anogenital and head and neck cancers. Hijacking of host cellular pathways is essential for virus pathogenesis; however, a major challenge remains to identify key host targets and to define their contribution to HPV-driven malignancy. The Hippo pathway regulates epithelial homeostasis by down-regulating the function of the transcription factor YAP. Increased YAP expression has been observed in cervical cancer but the mechanisms driving this increase remain unclear. We found significant down-regulation of the master Hippo regulatory kinase STK4 (also termed MST1) in cervical disease samples and cervical cancer cell lines compared with healthy controls. Re-introduction of STK4 inhibited the proliferation of HPV positive cervical cells and this corresponded with decreased YAP nuclear localization and decreased YAP-dependent gene expression. The HPV E6 and E7 oncoproteins maintained low STK4 expression in cervical cancer cells by upregulating the oncomiR miR-18a, which directly targeted the STK4 mRNA 3'UTR. Interestingly, miR-18a knockdown increased STK4 expression and activated the Hippo pathway, significantly reducing cervical cancer cell proliferation. Our results identify STK4 as a key cervical cancer tumour suppressor, which is targeted via miR-18a in HPV positive tumours. Our study indicates that activation of the Hippo pathway may offer a therapeutically beneficial option for cervical cancer treatment.
Identifiants
pubmed: 32555725
doi: 10.1371/journal.ppat.1008624
pii: PPATHOGENS-D-20-00115
pmc: PMC7326282
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Intracellular Signaling Peptides and Proteins
0
MIRN18A microRNA, human
0
MicroRNAs
0
Oncogene Proteins, Viral
0
RNA, Neoplasm
0
Transcription Factors
0
Tumor Suppressor Proteins
0
YAP-Signaling Proteins
0
YAP1 protein, human
0
STK4 protein, human
EC 2.7.1.11
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008624Subventions
Organisme : Medical Research Council
ID : MR/K012665/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M011151/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S001697/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 1052221/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/ K012665
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204825/Z/16/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T00021X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102174/B/13/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Cell Biol. 2003 Oct;5(10):914-20
pubmed: 14502294
Oncol Rep. 2015 Jun;33(6):2853-62
pubmed: 25963391
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Cancer Res. 1996 Oct 15;56(20):4620-4
pubmed: 8840974
PLoS Pathog. 2019 Jun 21;15(6):e1007835
pubmed: 31226168
Sci Transl Med. 2016 Aug 17;8(352):352ra108
pubmed: 27535619
Oncogene. 2002 Sep 5;21(39):6041-8
pubmed: 12203116
Anticancer Res. 2012 Sep;32(9):3835-40
pubmed: 22993326
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
Oncotarget. 2017 Jul 22;8(35):58061-58071
pubmed: 28938537
J Virol. 2003 May;77(10):6066-9
pubmed: 12719599
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817106
Nat Microbiol. 2016 Oct 31;2:16201
pubmed: 27798559
J Clin Invest. 2017 Apr 3;127(4):1338-1352
pubmed: 28240606
Oncogene. 2018 Sep;37(39):5257-5268
pubmed: 29855617
Expert Rev Mol Diagn. 2017 Jul;17(7):711-722
pubmed: 28597695
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
Oncotarget. 2017 Oct 6;8(61):103581-103600
pubmed: 29262586
Cancer Gene Ther. 2010 Dec;17(12):827-36
pubmed: 20885450
Oncogenesis. 2014 Apr 21;3:e99
pubmed: 24752237
PLoS Pathog. 2018 Apr 9;14(4):e1006975
pubmed: 29630659
Nat Rev Drug Discov. 2014 Jan;13(1):63-79
pubmed: 24336504
J Med Virol. 1994 Nov;44(3):243-9
pubmed: 7852968
Oncogene. 1998 Jun 11;16(23):3029-37
pubmed: 9662336
Oncogene. 2001 Jun 7;20(26):3354-62
pubmed: 11423986
PLoS Med. 2005 Jul;2(7):e163
pubmed: 16033304
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
Carcinogenesis. 2011 Mar;32(3):389-98
pubmed: 21112960
Oncotarget. 2015 Dec 29;6(42):44466-79
pubmed: 26561204
Genes Dev. 2010 Jan 1;24(1):72-85
pubmed: 20048001
Mol Cancer Res. 2012 Jul;10(7):904-13
pubmed: 22618028
Cancer Cell. 2009 Nov 6;16(5):425-38
pubmed: 19878874
Oncogene. 2016 Aug 4;35(31):4048-57
pubmed: 26657153
Cell. 2003 Aug 22;114(4):445-56
pubmed: 12941273
Cancer Res. 2012 Oct 15;72(20):5418-27
pubmed: 22942253
Sci Rep. 2017 Oct 27;7(1):14265
pubmed: 29079854
PLoS Pathog. 2016 Aug 02;12(8):e1005766
pubmed: 27483446
J Biol Chem. 2010 Dec 10;285(50):39108-16
pubmed: 20921231
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Dev Dyn. 2009 Jul;238(7):1627-37
pubmed: 19517570
J Am Board Fam Med. 2015 Jul-Aug;28(4):498-503
pubmed: 26152442
Sci Rep. 2018 Jun 25;8(1):9636
pubmed: 29941883
Anticancer Res. 2008 May-Jun;28(3B):1763-6
pubmed: 18630456
EMBO Mol Med. 2015 Sep 28;7(11):1426-49
pubmed: 26417066
J Biol Regul Homeost Agents. 2019 Mar-Apr;33(2):321-330
pubmed: 30972994
Oncogene. 2013 Jan 3;32(1):106-16
pubmed: 22330141
Genes Chromosomes Cancer. 2008 Sep;47(9):755-65
pubmed: 18506748
Biochemistry. 2016 Oct 4;55(39):5507-5519
pubmed: 27618557
Heliyon. 2015 Dec 23;1(4):e00049
pubmed: 27441232
Cell. 2006 Jan 27;124(2):267-73
pubmed: 16439203
Cancers (Basel). 2018 Dec 05;10(12):
pubmed: 30563114
Gut. 2018 Sep;67(9):1692-1703
pubmed: 28866620
J Virol. 2020 Jun 1;94(12):
pubmed: 32238586